OstemiR: A Novel Panel of MicroRNA Biomarkers in Osteoblastic and Osteocytic Differentiation from Mesencymal Stem Cells by Watanabe, Ken et al.
 
OstemiR: A Novel Panel of MicroRNA Biomarkers in Osteoblastic
and Osteocytic Differentiation from Mesencymal Stem Cells
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Eguchi, Takanori, Ken Watanabe, Emilio Satoshi Hara, Mitsuaki
Ono, Takuo Kuboki, and Stuart K. Calderwood. 2013. OstemiR: A
novel panel of microRNA biomarkers in osteoblastic and
osteocytic differentiation from mesencymal stem cells. PLoS ONE
8(3): e58796.
Published Version doi:10.1371/journal.pone.0058796
Accessed February 19, 2015 12:01:29 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10622996
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAOstemiR: A Novel Panel of MicroRNA Biomarkers in
Osteoblastic and Osteocytic Differentiation from
Mesencymal Stem Cells
Takanori Eguchi
1,2*, Ken Watanabe
3, Emilio Satoshi Hara
4, Mitsuaki Ono
4, Takuo Kuboki
4,
Stuart K. Calderwood
2*
1Department of Oral Disease Research, National Center for Geriatrics and Gerontology, Obu, Japan, 2Division of Molecular and Cellular Biology, Department of Radiation
Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America, 3Department of Bone and Joint Disease,
National Center for Geriatrics and Gerontology, Obu, Japan, 4Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of
Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Abstract
MicroRNAs (miRNAs) are small RNA molecules of 21–25 nucleotides that regulate cell behavior through inhibition of
translation from mRNA to protein, promotion of mRNA degradation and control of gene transcription. In this study, we
investigated the miRNA expression signatures of cell cultures undergoing osteoblastic and osteocytic differentiation from
mesenchymal stem cells (MSC) using mouse MSC line KUSA-A1 and human MSCs. Ninety types of miRNA were quantified
during osteoblastic/osteocytic differentiation in KUSA-A1 cells utilizing miRNA PCR arrays. Coincidently with mRNA
induction of the osteoblastic and osteocytic markers, the expression levels of several dozen miRNAs including miR-30 family,
let-7 family, miR-21, miR-16, miR-155, miR-322 and Snord85 were changed during the differentiation process. These miRNAs
were predicted to recognize osteogenic differentiation-, stemness-, epinegetics-, and cell cycle-related mRNAs, and were
thus designated OstemiR. Among those OstemiR, the miR-30 family was classified into miR-30b/c and miR-30a/d/e groups
on the basis of expression patterns during osteogenesis as well as mature miRNA structures. In silico prediction and
subsequent qRT-PCR in stable miR-30d transfectants clarified that context-dependent targeting of miR-30d on known
regulators of bone formation including osteopontin/spp1, lifr, ccn2/ctgf, ccn1/cyr61, runx2, sox9 as well as novel key factors
including lin28a, hnrnpa3, hspa5/grp78, eed and pcgf5. In addition, knockdown of human OstemiR miR-541 increased
Osteopontin/SPP1 expression and calcification in hMSC osteoblastic differentiation, indicating that miR-541 is a negative
regulator of osteoblastic differentiation. These observations indicate stage-specific roles of OstemiR especially miR-541 and
the miR-30 family on novel targets in osteogenesis.
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Introduction
RNA transcripts from the genome spontaneously form stem,
loop and/or bulge structures, and many of these have been
reported to act as primary miRNA (pri-miRNA). Drosha, an
RNase III in mammalian, then cuts the pri-miRNA to create pre-
miRNA that has a simpler stem-bulge structure. Exportin-5
subsequently exports the pre-miRNA to the cytoplasm [1,2].
Dicer, another RNase III, next cuts the pre-miRNA and creates
double strand RNA (dsRNA). Each strand of the dsRNA is a 21–
25mer nucleotide, and acts as miRNA by forming the RNA-
induced silencing complex (RISC) along with the Argonaute
protein [3]. The miRNAs can then hybridize partially with
mRNAs, inhibit mRNA translation [4] and promote mRNA
degradation [5,6]. Small RNAs have been also reported to
regulate transcription in fission yeast [7], in Drosophila [8] and in
human [9]. Moreover, miRNA have also been detected in
exosomes suggesting a potential role in regulating gene expression
in a paracrine or autocrine manner [10]. Recent studies also imply
that miRNA may be involved in a feedback system of gene
expression where the miR-371-373 cluster was controlled by Wnt
target beta-catenin/TCF and this miRNA cluster could then
inhibit DKK1, a Wnt/LRP inhibitor [11].
Osteoblasts are crucial for bone formation during development
and metabolism in adult animals by coupling with osteoclasts and
thus playing key roles in osteocytic differentiation. Runx2/Cbfa1,
Sp7/Osterix and beta-catenin, which are the master transcription
factors for osteocytic differentiation, regulate the differentiation of
osteoblasts [12,13]. In addition, the CCN family proteins are
known as crucial growth factors for bone formation [14]. The
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e58796ccn2/ctgf gene is inducible by TGF-beta/smad and through
TRENDIC [15,16], and is expressed in mesenchymal/fibroblast
and vascular endothelial lineages to induce chondro-, and osteo-
genesis in target cells [17,18]. Recent studies have demonstrated
that beta-catenin/T-cell factor (Tcf)/lymphoid enhancer factor
(Lef) shares a binding site with sox9, a master transcription factor
for chondrogenesis, in the ctgf/ccn2 promoter region and provides
stage specific control of ctgf/ccn2 expression [19].
Osteocytes, the terminally differentiated cells derived from
osteoblasts, are crucial for the mechanotransduction/mechano-
stress response, leading to inhibition of osteoclastic bone resorp-
tion, mineralization, and mechanical strengthening of bone while
preventing osteoporosis and fracture [20,21,22]. Osteoblasts are
differentiated cells derived from mesenchymal stem cells or bone
marrow stromal cells [23], and can further maturate to form
osteocytes, which reside individually in bone cavities called lacunae
[24]. Dmp1, Fgf-23 and sclerostin are known osteocyte markers
[20,25]. Dmp1, which is a secretory protein, was the first osteocyte
marker to be isolated [26]. In addition, FGF-23 plays an important
physiological function in mineral homeostasis and bone formation
in the body by modulating phosphate excretion and vitamin D
activation in the kidney [27,28]. Finally, sclerostin, the Wnt
antagonist and the product of the sost gene that inhibits bone
formation and plays a causal role in sclerosteosis, is transcription-
ally activated by mef2c and is another osteocyte marker [29,30].
Induction of bone formation by PTH/PHT1R-induced downreg-
ulation of SOST expression is mediated through MEF2 [31].
In this study, we have carried out a series of experiments on
KUSA-A1, a murine bone-marrow-derived mesenchymal stem
cell line with the potential to differentiate into several different cell
types, although being highly oriented towards osteocytic differen-
tiation [32]. KUSA-A1 cells produce rich amounts of alkaline
phosphatase (ALP), synthesize bglap/osteocalcin that encodes the
bone gamma-carboxyglutamic acid-containing (gla) protein and
mineralize very efficiently [32]. The KUSA-A1 cells present Sca-1,
CD44, Ly-6C and CD140 markers on the surface [33]. More
significantly, subcutaneous injection of KUSA-A1 cells in mice
generates ectopic bone formation.
Previous studies have shown that miRNAs regulate osteoblastic
differentiation. miRNAs control the readout of the mRNAs
encoding Runx2 [33], FAK [35] and Connexin43 [36] and thus
regulate osteoblastic differentiation. In our study, we have
analyzed alterations in the miRNA expression signature associated
with osteoblast maturation and/or osteocytic differentiation
utilizing a qRT-PCR-based miRNA array. We then investigated
the relationship between osteocytic differentiation and the
deduced patterns of miRNA expression.
Materials and Methods
Cell culture, osteo-induction
Mouse mesenchymal stem and bone marrow stromal cell
(mMSC) line KUSA-A1 and calvaria-derived osteoblastic cell line
MC3T3-E1 were provided from the RIKEN cell bank. These cell
lines were cultured in DMEM supplemented with 10% FBS in
humidified air containing 5% CO2 at 37uC. For osteogenic
induction, cells were cultured until confluency, and then L-
ascorbic acid phosphate, dexamethasone and beta-glycerophos-
phate (DS pharma) were added every other day for osteogenic
differentiation.
Human bone marrow stromal cells (hBMSCs, hMSCs) were
purchased from Lonza (Lonza Group, Walkersville, USA) and
maintained in basal medium (Invitrogen, Carlsbad, CA, USA)
containing 15% fetal bovine serum (FBS, Invitrogen), 1%
penicillin and streptomycin (Sigma, St Louis, MO, USA), 1% L-
glutamine (Invitrogen) and 180 nM of ascorbic acid 2-phosphate
(Wako Pure Chemical Industries, Osaka, Japan). For induction
toward osteogenic lineage, hMSCs were cultured until confluency
and medium was then substituted to osteogenic-induction
medium, which was consisted of basal medium supplemented
with b-glycerophosphate (10 mM, Sigma), dexamethasone
(10610
28 M, Sigma) and KH2PO4. (Katayama Chemical Indus-
tries, Osaka, Japan). Osteogenic medium was changed twice a
week.
Alizarin red staining
For alizarin red staining, cells were fixed with 4% PFA for
15 min, washed with distilled water, stained with 1% Alizarin red
S staining solution for 20 min, and then washed again to remove
excess dye as previously described [37].
miRNA qPCR array
Total RNA including small RNA was prepared by using Qiazol
and miRNeasy mini kit (Qiagen) with DNase treatment. cDNA
was synthesized with a stem-loop adaptor by using RT2 First
Strand kit (SABiosciences). miRNA qPCR array was carried out
by using miFinder miRNA PCR array (SABiosciences). The data
were analyzed by using miScript array data analysis (SABios-
ciences).
mRNA qRT-PCR (realtime PCR)
Primer pairs for mRNA were designed by utilizing the NCBI
gene bank, primer 3 software and perfect PCR system (TaKaRa),
in which each 59- and 39- primer are designed to recognize
different exons for avoiding genomic DNA amplification if
available. cDNA synthesis was carried out using mixture of
random primer and oligo dT. The cDNA was diluted 4-fold in
TE0.1 (10 mM Tris and 0.1 mM EDTA). A mixture of samples
and step dilutions (10-fold and 100-fold) were used as a standard to
clarify amplification efficiency. Realtime PCR was carried out as
described previously [15]. Expression levels were normalized to
that of the internal control gapdh or S29. Relative mRNA levels
among different gene products were obtained utilizing DDCt
calculation. DDCt method when amplification efficiencies were
similar among those.
miRNA qRT-PCR
Forward primers specific for each mature miRNA, which detect
both human and mouse miRNAs, were designed based on
sequence of mature miRNA obtained from the miRBase [38].
cDNA was synthesized by A-tailing and reverse transcription using
universal primer by using qScript microRNA cDNA synthesis kit
(QuantaBiosciences), the All-in-One miRNA qRT-PCR kit (Gene-
Copoeia) or Mir-X
TM miRNA first-strand synthesis. cDNA was
diluted 4–20 fold in TE0.1 and step dilution was prepared as
describe above. Realtime PCR for miRNA was carried out: 95uC
for 5 min initially, then 30–50 cycles of 95uC for 5 s and 60uC for
40–60 s, and final dissociation analysis. miRNA levels were
normalized to that of the internal control snord48 or snord66.
miRNA target prediction
TargetScan 5.1 was utilized either for in silico search for
miRNAs which recognize 39-untranslated region (39-UTR) in a
specific mRNA of interest or for prediction of target mRNA of
specific miRNA of interest [39]. Target of miR-30 family, miR-34
family, let-7 family, miR-15/16 family (including miR-322/424),
miR-21 family, miR-541/654 was predicted and selected using cut
microRNAs for MSC Osteogenic Differentiation
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transcription, protein modification-related factors were preferen-
tially selected.
Statistics
Data was expressed as means6standard deviations, and the
statistical significance of differences in mean values was assessed by
Student’s unpaired t tests for KUSA-A1 cells or by one-way
ANOVA with Tukey post-hoc correction tests for hBMSC/MSC.
Differences among the mean values were considered significant at
a P of ,0.05. Realtime PCR was repeated 4 times for each
samples in experiments using KUSA-A1 cells. Total RNA was
isolated from independent triplicate culture of hBMSC/MSC and
realtime PCR was repeated in triplicate.
Stable miRNA expression
miRNA sequences of step loop part of pre-miR-21, pre-miR-
30d, and pre-miR-322 were obtained from miRBase. The
genomic counterparts of the miRNA stem loop were searched
using Blast. Hundred base native flank sequences to both upstream
and downstream of the miRNA stem loop were added for PCR
amplification using following primers: miR21-F, cagctttctttccta-
gaattggcattaag; miR21-R, ccaaggtataagggctccaagtctcac; miR30d-
F, ttattgtttgtcttttccccccaagatg; miR30d-R, ttagaagctgccagcagaag-
caagcag; miR322-F, tcctccccactatccaccacaccctg; miR322-R,
caggcccttggactgtgtagagtgac. The amplified fragments were cloned
into pSMPUW-miR-GFP/Puro (Cell Biolabs, San Diego, CA) and
sequenced to verify the contents. Recombinant lentivirus was
generated by Lenti-X Lentiviral expression system (Takara Bio,
Shiga, Japan) and infected to KUSA/A1 cells for 36 hours, and
then the medium was replaced to normal medium. The infected
cells were selected by puromycin (2 ug/mL) in 10 days for cloning
of miR-21 and miR-30d stable transfectant and in 2 weeks for
miR-322 stable cells.
Anti-miRNA-mediated knock down
Cells were plated in 6 well plates at a density of 26105 cells with
culture medium without antibiotics. On the following day, cells
were transfected with anti-miR541miR-541 (20 nM, miRvana
TM
miRNA inhibitor, Invitrogen) or negative control (20 nM,
mirVana
TM miRNA Inhibitor negative control #1, Invitrogen)
using RNAiMax (Invitrogen). Cells were cultured for 2 days before
total RNA extraction, or culture until confluency before osteogenic
induction.
Results
Osteoblastic and osteocytic differentiation of KUSA-A1
cells
We first investigated KUSA-A1, MC3T3 cells and hBMSC/
hMSC in tissue culture as osteoblastic/osteocytic differentiation
models (Fig. 1). After adding osteogenic differentiation supple-
ments to cells, calcium was gradually deposited in KUSA-A1 and
hMSC culture until 2 weeks after the addition (Fig. 1). The levels
of calcium deposition were markedly increased in KUSA-A1 cells
after 2 weeks induction, while only mild levels were observed in
MC3T3 cells. KUSA-A1 cells were therefore used in the
subsequent studies on miRNA signature involved in osteocytic
differentiation from MSCs. In order to confirm the differentiation
stages, relative expression of markers for mesenchymal, osteoblas-
tic and osteocytic cells were quantified after osteogenic induction.
Mesenchymal cell markers ctgf/ccn2, cyr61/ccn1 and nov/ccn3 were
induced at initial stimulation (4 hrs) but declined as cells
differentiated along the osteocyte lineage (4w+: Fig. 2A). The
Osteoblast marker spp1/osteopontin, increased on 4 hours (0.16
day), 2 days, 7 days and 14 days after starting osteogenic induction
(Fig 2B), and the spp1 level remained at a decreased level in
confluent cells without osteoinduction. Another osteoblast marker
Bglap/osteocalcin was induced at 2 weeks after osteoinduction
compared with non-induced control (Fig 2B). Dmp1, an osteocyte
marker, was powerfully induced at 4 hours, 7 days and 14 days
after osteo-induction (Fig. 2C). Late stage osteocyte marker sost/
sclerostin was increased on day 2 and especially on day 14, while
under detection limit on other conditions and time points (Fig 2C),
These results suggest that this MSC differentiation model of
KUSA-A1 is useful for analysis of either osteoblastic and/or
osteocytic differentiation from MSCs.
Osteoblastic differentiation of hMSC/hBMSC
In order to firstly establish osteoblastic differentiation from
hMSC, osteo-induction, calcium staining and quantification of
mRNA levels of marker genes were carried out. Calcium was
accumulated on hMSC upon osteo-induction around 1 and 2
weeks after the induction gradually as shown by alizaline red S
staining (Fig 1), while non-osteo-induced cells were not stained.
ALP and SPP1/Osteopontin (OPN) mRNA were quantified in
realtime qRT-PCR during osteo-induction. Both ALP and OPN/
SPP1 were upregulated in two independent experiments with
different peak timings. In the first sample, both ALP and OPN/
SPP1 peaked on day14, while in the 2nd sample, both ALP and
OPN/SPP1 peaked on day 7 and decreased thereafter (Fig 2D),
indicating that differentiation is slower in sample #1, while faster
in sample #2 relatively each other. These data suggest that
hMSC/hBMSC differentiated into osteoblasts after the induction.
Overview of the miRNA array approach
To investigate novel miRNAs that could potentially regulate
osteoblastic/osteocytic differentiation and stemness (OstemiR), a
screening with a qRT-PCR-based miRNA array was utilized. We
first obtained an overview of changes in overall miRNA levels.
Figure 1. Calcium deposition on KUSA-A1, hBMSC/hMSC and
MC3T3-E1 cells during osteogenic differentiation. Cells were
cultured with (+) or without (2) L-ascorbic acid phosphate, dexameth-
asone and beta-glycerophosphate. Calcium deposition was visualized
by alizarin red S staining.
doi:10.1371/journal.pone.0058796.g001
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were significantly lower than observed in other conditions (Fig. 3A).
All the tested miRNAs were then analyzed by clustergram and the
findings indicated that most miRNAs were expressed at a reduced
level in mature osteocytes (Fig. 3B). Based on the results of the
clustergram, miRNAs were then categorized into eight groups
(Table 1). The most abundant group was the miRNAs that
increased in level after prolonged culture without osteo-induction
(2w2). miRNA downregulated by two weeks osteo-induction
included members of the let-7 and miR-30 families (miR-30a/d/e)
(Table 1). Thus, the total amount of miRNA is reduced in
osteocytes compared to osteoblast precursors, and release of
translational repression may be involved in induction of osteocyte-
specific factors and the osteocytic phenotype.
For a better understanding of OstemiR, the miRNAs involved
in osteocyte differentiation, heat maps were created to compare
miRNA expression levels between experimental conditions of
induction (4h and 2w+/2 differentiation stimulus). The expression
level of miR-30d was higher in the 4h+, 2w- and 2w+ condition
than in the 4h2 condition (Fig. 4A–F). Indeed, by a single
stimulation for osteocytic differentiation, not only the miR-30d but
also miR-155 was induced (Fig. 4A, D). The expression level of
miR-16 was decreased by the single stimulation (Fig. 4A, D). After
repeated osteo-induction (2w+), miR-30d and miR-30c were
induced, and the expression levels of miR-503, miR-322 and miR-
125b-3p were the most powerfully repressed (Fig. 4B, E). miR-30d
and miR150 as well as other miRNAs were induced by long-term
culture for 2 weeks in the absence of differentiation stimulus, while
miR-503 and miR-744 were reduced by the long-term culture
(Fig. 4C, F).
Standardized quantification of miRNA expression
In order to establish an internal control for miRNA quantifi-
cation in the KUSA-A1 cell during the conditions of osteocytic
Figure 2. Marker expression pattern during KUSA-A1 mMSC line with (Os+) or without (Os2) induction of osteoblast
differentiation. (A) Cyr61/ccn1, ctgf/ccn2 and nov/ccn3 mRNAs were quantified as osteo-chondro-mesenchymal cell markers in initial differentiation.
(B) Spp1/osteopontin and bglap/osteocalcin mRNAs were quantified as osteoblastic markers. (C) Dmp1 and sost/sclerostin mRNA were quantified as
osteocyte markers. *, P,0.05 (n=4). ud, undetected. (D) ALP and OPN/SPP1 mRNA expression pattern during hBMSC/MSC osteogenesis.
doi:10.1371/journal.pone.0058796.g002
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expression patterns were examined from the results of the miRNA
array (Fig. 5A). Among these candidate control RNAs, the
expression patterns of Snord66 and PPC were found to be the
most stable in all-experimental conditions, while Rnu6 was not
stably expressed, and Snord85 levels became elevated after 2
weeks of osteo-induction. Therefore, Snord66 or PPC were
adopted as internal controls for miRNA quantification in the
KUSA-A1 osteocytic differentiation system in later experiments.
In addition, Snord85 was established as a novel marker of
osteocytic differentiation.
We next attempted to confirm the reliability of the results of the
miRNA array analysis, designed specific primers for each miRNA,
and quantified miRNA levels using qRT-PCR. Expression of both
miR-21 and miR-155 was stimulated by the initial differentiation
stimulus (4h+) although expression was suppressed at the terminal
differentiation stage (2w(+) as indicated by both qRT-PCR and
miRNA array (Fig. 5B, C, D). miR-322 was investigated by the
same methodology, and shown to be decreased at 2 weeks after
osteo-induction in both the qRT-PCR and miRNA array (Fig. 5E,
F). miR-16 was also repressed by osteogenic stimulus as quantified
by either miRNA array or qRT-PCR (Fig. 5G, H). miRNA array
analysis showed that miR-30d was induced by single stimulation
(4h+), repeated stimulation (2w+) and prolonged culture in the
absence of stimulation (2w2). However, miR-30d was increased
only by single stimulation as indicated by qRT-PCR (Fig. 5I, J).
Overall, these results indicate that while the qRT-PCR-based
miRNA array is useful and reliable for screening, individual qRT-
PCR is more reliable and flexible for the assay of single-peaked
amplification of cDNA in detailed kinetic analysis.
Figure 3. miRNA expression signature during MSC osteocytic differentiation. (A) Difference in miRNA expressions among experimental
conditions with or without induction for 4 hours or 2 weeks. (B) Clustergram of miRNA expression in KUSA-A1 cells with or without osteo-induction
for 4 hours or 2 weeks. Red and green indicate relatively high and low expression levels, respectively.
doi:10.1371/journal.pone.0058796.g003
microRNAs for MSC Osteogenic Differentiation
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osteoblastic/osteocytic differentiation
The functions and targets for OstemiRs, whose expression levels
were significantly changed during osteocytic differentiation, were
predicted by analysis of database (Table 2). These OstemiRs were
predicted to recognize mRNAs encoding a number of key
transcription factors for osteocytic differentiation. These included:
(runx2, sox9, sox5, smad family, msx1, tcf, jun and fos), transcription
factors for pluripotency (sox2, klf5/klf, mycn), EMT-related factors
(snail, zeb2, claudin-1/2), essential growth factors for osteocytic
differentiation and their receptors (wnt/lrp, fgf/fgfr, bmp/gdf/bmpr/
tgfbr/actvr, ihh, lifr, notch, igf/igfr, insr), matrix-related molecules (reck,
timp), neuronal markers (gfap), epigenetic factors (mll, jmj, jhdm,
hdac/sirt1, tet, jarid, mbd, ncoa1), cell cycle proteins (cyclin/cdk) and
Table 1. miRNA groups categorized by expression pattern.
Expression miRNA Possibility #1 Possibility #2
high in 4h, low in 2w miR-15b, 125a-5p, 92a, 744, 29b, 146a, 124, 21, 18a, 322,
125b-5p, 182, Rnu6
Stemness marker Differentiation inhibitor
high in 2w, low in 4h 30d Differentiation marker Stemness inhibitor
high in 4h+, low in 4h2 miR-155, miR-541, miR-21 Initiator of Differentiation Inhibitor or maintiner of
stemness
high in 4h2, low in 4h+ miR-30d Inhibitor of Initiation Inhibitor or maintainer of
stemness
high in 2w+, low in 2w2 No miRNA in this pattern was observed. Osteocyte marker Stemness inhibitor
high in 2w2, low in 2w+ miR-18a, 322, 125b-5p, 182, 872, 130a, 191, 28, 425, 196a, 93 Osteocyte negative marker Stemness marker
high only in 2w+ Snord85 Osteocyte marker Stemness inhibitor
high only in 2w2 miR-101a, 16, 23b, 23a, 9, 24, 467c, 140, 10b, 467e, 29a, 27b, 150,
199a-5p, 199b, 218, 17, 126-3p, 99a, 10a, 30e, 19b, 126-5p, 196b, 25, 96,
186, 106b, 31, 22, 140, 30a, 374, 34c, 27a, 880. let-7i, 7g, 7f, 7a, 7b, 7c, 7d
Osteocyte negative marker Stemness marker
Possible functions of miRNAs were shown in right.
doi:10.1371/journal.pone.0058796.t001
Figure 4. Heat maps and scatter plot analysis of miRNA array. Upregulated miRNA (red) and downregulated miRNA (green) were colored and
listed. miRNA expression after 4 hours of osteo-induction (4h+, A, D), osteo-induction for 2 weeks (2w+, B, E) or 2 weeks of long culture (2w2,C ,F )
were compared to non-induction control (4h2).
doi:10.1371/journal.pone.0058796.g004
microRNAs for MSC Osteogenic Differentiation
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which was upregulated during osteoblast maturation, including
miR-30d, miR-155, miR-21 and miR-16, constitutes a marker of
osteocytic differentiation and these miRNA may possibly repress
stemness maintenance in osteoblasts. Both miR-34c and miR-16,
which increased at 2w+, the stage of osteocytes, are possibly
osteocyte markers and repressors of osteoblast-maintaining genes.
Prediction of miRNAs that target osteo-regulators
By the prediction of miRNAs that target osteo-regulators,
miRNA recognition sites in the 39-UTR regions in the target
mRNAs were predicted and classified into groups that were: (a)
conserved among all vertebrates, (b) conserved only among
mammalian species or (c) poorly conserved. The conserved
miRNA recognition sites among all vertebrates (a) and only
among mammalians (b) are described below. A let-7/miR-98
recognition site was predicted in the 39-UTR region of dmp1
mRNA with broad conservation among vertebrates (Fig. S1).
Since all members of the let-7 family are downregulated during
osteocytic differentiation (Table 1) it was predicted that the
downregulation of the let-7 family could be associated with an
eventual repression of the dmp1 gene. In addition, miR-30d was
induced by osteo-induction (Fig. 5J), and miR-30 family recogni-
tion sites were found in the 39-UTR regions of the runx2 and nov/
ccn3 mRNAs (Fig. S2, S3). Moreover, the miR-30 family was
predicted to recognize sox9, lrp6, smad2, smad1, notch1, bdnf and a
number of epigenetic factors (Table 2). These findings suggest that
members of the miR-30 family could play an essential role in
Figure 5. Quantification of miRNA expression levels during osteocytic differentiation. (A) Expression of internal controls for miRNA
quantification. Snord85, Snord66 and Rnu6 levels during osteogenesis of KUSA-A1 were quantified in PCR array. miRTC, miRNA reverse transcription
control. PPC, positive PCR control. (B–K) Quantification of miRNA expression levels by using miRNA array (B, E, G, I, K) or qRT-PCR (C, D, F, H, J). Values
were normalized to snord66 levels (C, D, F, H, J). *, P,0.05 (n=4). n.s., not significant.
doi:10.1371/journal.pone.0058796.g005
microRNAs for MSC Osteogenic Differentiation
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PLOS ONE | www.plosone.org 8 March 2013 | Volume 8 | Issue 3 | e58796osteocytic differentiation. Moreover, among miRNAs that were
predicted to recognize the 39-UTR of ctgf/ccn2, an osteo2,
chondrogenesis factor, and miR-18ab and miR-19 are also
OstemiR, which increased during osteocytic differentiation (Fig.
S4, Table 1).
miR-30 expression pattern during KUSA-A1 MSC
osteocytogenesis
In the miRNA PCR array, miR-30d showed an increased
expression level in osteocytogenesis of KUSA-A1. Since miR-30
family members are homologous (Fig 6A) and possibly share
targets, we further investigated the miR-30 family expression
patterns at four time points with or without osteo-induction. As a
result, miR-30a, miR-30c and miR-30d were highly expressed
compared with miR-30b or miR-30e (Fig. 6B). All the miR-30
members once reduced during osteoblastic differentiation stage on
day 2 and day 7. Among those members, miR-30a/d/e were
increased on day 14 around a late osteocytic stage (Fig 6A). These
data suggest that miR-30 members could be repressing targets at
the MSC and osteocytic stages, while repression on target mRNA
may be relieved during the intermediate osteoblastic stage.
Prediction of miR-30 targeting
miR-30 targets were predicted using TargetScan. Putative
targets with strong scores were selected by a cut-off score 20.4.
Factors related to development (runx2, eed, sox9, lifr, lrp6, ctgf),
epigenetics (wdr82, brwd1, pcgf5, eed), transcription and cell cycle
(zbtb41, zbtb44, ccnt2, ccne2), RNA biogenesis (hnRNP3, Lin28A,
Lin28B, helz), post-translational protein modification (snx16, yod1)
and known targets (runx2, ctgf, grp78/hspa5) are shown in the list
(Table 3). These predictions appear to be specific to each of the
miR-30 members; however, 11 nt of the 59 seed sequence in miR-
30 family members are common and the mature miR-30s
sequences are quite homologous among miR-30a/d/e or between
miR-30b/c (Fig 7A), indicating shared and distinctive targets
among miR-30 members.
Searching 39-UTR of putative target mRNA, targeting
sequences which can make base pairing with 59 seed sequences
of miR-30 were found in the 39-UTR of lifr, eed, pcgf5 and sirt1
utilizing TargetScan (Fig 7B). One miR-30 targeting sequence in
the 39-UTR of ctgf/ccn2 has been reported. In addition, two
putative miR-30 targeting sites on spp1/osteopontin were found.
Matching around the 39 part and intermediate part of miR-30
were tested to those targets. Not only 59 seed sequences but also 39
sequences of miR-30d matched to the lifr, eed and sirt1 39-UTR.
On the other hands, miR-30b/c 59 seed as well as 39 part was
matched with 39-UTR sequences of spp1/opn, pcgf5, hspa5/grp78
and ctgf/ccn2. These in silico analyses suggested putative shared and
distinctive target mRNA recognition by miR-30 family, the groups
of miR-30a/d/e and miR-30b/c.
miR-30 targeting in mMSC line
In order to clarify the function of miR-30d on target mRNAs,
qRT-PCR was carried out in stable miR-30d transfected KUSA-
A1 and in control vector transfectant. In a result, hnrnpa3 variant B
level in proliferating/sparse miR-30d tranfectant was around 50%
lower than that in the vector transfected control (Fig 8A), while no
significant change in confluent cells (Fig 8B), indicating context
dependent repression of hnrnpa3 vB by miR-30d. Lin28a mRNA
level in confluent miR-30d tranfectant was around 50% lower
than that in the vector transfected control (Fig 8A, left), while
around 50% higher in proliferating cells (Fig 8A, right), indicating
context dependence as well. Ccn2/ctgf and ccn1/cyr61 mRNA levels
in confluent miR-30d cells were lower than those in the control
(Fig 8B), while these gene product levels in proliferating miR-30d
cells were higher than those in the control (Fig 8A). Runx2 and sox9
mRNA level in miR-30d transfectants were higher than that in the
control (Fig 8AB). Hspa5/grp78, lifr, eed, opn/spp1 and pcgf5 mRNA
levels in miR-30 transfected cells were 20–30% lower than those in
control cells in both proliferating and confluent cells (Fig 8AB),
indicating direct repression of mRNA stability. These data
suggested targets of miR-30d and context-dependent effect of
Figure 6. Mature miR-30 quantification during osteocytogenesis. (A) miR-30 family expression pattern in KUSA-A1 mMSC line with (red bars,
Os+) or without (blue bars, Os2) osteoinduction. Values were normalized to snord48 levels. (B) Relative expression levels among miR-30 family
members on day 14. Note the different expression levels: miR-30d.30a.30e: miR-30c.30b. *, P,0.05 (n=4).
doi:10.1371/journal.pone.0058796.g006
microRNAs for MSC Osteogenic Differentiation
PLOS ONE | www.plosone.org 9 March 2013 | Volume 8 | Issue 3 | e58796Figure 7. miR-30 targeting prediction. (A) List of mature miR-30 family members. Homologous nucleotides among miR-30a/d/e or between miR-
30b/c were shown in bold. (B) Base pairing prediction between miR-30 and target sequences in the 39-UTR of SPP1/osteopontin, HSPA5/GRP78, LIFR,
EED, PCGF5, SIRT1 and CTGF/CCN2. Note that targeting can be shared among some family members. Positions in 39-UTR were shown below the
sequences.
doi:10.1371/journal.pone.0058796.g007
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PLOS ONE | www.plosone.org 10 March 2013 | Volume 8 | Issue 3 | e58796miR-30d on RNA regulators including lin28 and hnRNPA3 and on
differentiation regulators including runx2, sox9 and ccn1/2.
Expression pattern of miR-30 targets
For a better understanding of miR-30 targeting, basal mRNA
expression levels of 18 gene products were quantified and
compared in proliferating/sparse KUSA-A1 cells (vector trans-
fected control cells). HspA5/grp78, ccn1/cyr61, spp1/opn, hnrnpa3 vB,
lifr, pcgf5, eed and ctgf/ccn2 were detected in high-level expression
levels (Fig 9A). Hnrnpa3 vC, wdr82, runx2, sox9, yod1 and lin28a were
detectable levels and quantitated. The expression levels of lrp6,
sirt1 and lin28b were quite low. The mRNA levels of ccn3/nov and
sox2 were under detection limit (Fig 9A). Interestingly, RNA
regulators (lin28a, hnrnpa3 vC) and differentiation-related factors
(ccn2, ccn3, runx2, sox9) were expressed in proliferating KUSA-A1
cells, while suppressed in confluent cells (Fig 9B). These mRNA
including runx2, ccn2/ctgf, ccn3/nov and opn/spp1 (Fig 2) were again
induced upon osteo-induction (Fig 2). Oppositely, hnrnpa3 vC and
lifr mRNA levels increased in confluency compared with those in
proliferating cells (Fig 9B). These results suggest that many gene
products encoding growth factors and transcription factors were
powerfully expressed in proliferating cells compared with idling
cells, while only lifr and hnrnpa3 vC mRNA are increased in idling
confluent cells compared with proliferating cells.
Furthermore, mRNA expression pattern of miR-30d targets
during osteogenesis of KUSA cells were quantified. Lin28a mRNA
was remarkably induced during the osteogenesis, and reached
around 200-fold on day 14 (osteocytic stage) compared with the
day 0 (Fig 9C), indicating its essential role and possible release of
repression during osteogenesis. Pcgf5 mRNA levels decreased, and
reached to the half on day 14 compared with the level on day 0
(Fig 9C). Hnrnpa3 variant c, eed and hspa5 mRNA were
immediately induced by the osteo-inductive stimulation by 13-
fold, 8.1-fold and 4.4-fold respectively, and thereafter kept around
half levels of the maximum levels (Fig 9D). These immediate early
induction followed by quick attenuation patterns were shared with
those of CCN gene family shown in Fig 2A, indicating these 6 kinds
of transcripts are under the control of same factors and the miR-30
family. Distinctively from the variant C, hnrnpa3 variant B, the
major variant, mRNA was gradually reduced upon osteocytogen-
esis (Fig 9F), indicating osteo-induction controls splicing of
hnRNPA3 mRNA. Both runx2 and lifr mRNA were immediately
reduced at 4 hours after the stimulation, and thereafter recovered
in 2 days (Fig 9E). Then lifr mRNA level was reduced to the day
Table 3. List of predicted miR-30 targets.
miRNA targets score Note Class
Protein
locality
miR-30b SNX16 21.2 Phosphatidil inositol binding (Phox) domain, protein trafficing. Phos Sig C
miR-30b Runx2 21 Master transcription factor for osteoblast differentiation. Known target of miR-30. Dev, Txn N
miR-30b hnRNPA3 20.96 hnRNPA family directly bind to mRNA for nuclear export. hnRNPA1 binds Pri-let-7a-1and
inhibit Drosha cleavage.
RNA N/C
miR-30b EED 20.9 Embryonic ectoderm development. polycomb group (PcG), Component of PRC2/EED-EZH2
complex. K9/K27 methylation for repression. Control ES cell self-renewal loop with Sox2.
interact with integrin beta7 (may mediate integrin signal), interact with HDAC for histone
deacetylation. WD protein associated, miR-30-specificity.
Dev, Epige, Stem N, Chro
miR-30b CCNE2 20.84 G1/S transition Cell cycle N
miR-30b YOD1 20.7 DeUbiquitination enzyme Protein Modi
miR-30b WDR82 20.61 WD repeat domain protein. let-7g is generated from WDR82 intron. Txn N
miR-30b Sox9 20.6 Master transcription factor for chondrogenesis Dev, Txn N
miR-30b LIFR 20.6 Key factor for ES cell self-renewal. making heterodimer with gp130. Ligands are LIF and
oncostain M. A member of IL-6 receptor family.
Stem, Dev, signals M
miR-30b LRP6 20.5 Frizzled co-receptor for Wnt signaling Dev, signal M
miR-30b LIN28A 20.46 Inhibit pri-let-7 maturation in cytoplasm. Reprogramming factor. Containing CSD and
CCHC 62.
RNA, Stem C
miR-30e LIN28B 20.71 Inhibit pri-let-7 maturation in nucleus. Reprogramming factor. Containing NoLS and
NLS in addition to LIN28A.
RNA, stem N
miR-30c S100PBP 21.19 Ca, Zn/transport
miR-30c ZBTB41 20.92 Zinc finger and BTB domain containing 41 Txn N
miR-30c CCNT2 20.49 Transcription, component of pTEFb with CDK9. phosphorylation of RNA polymerase II
CTD for transcription elongation
Txn Chro
miR-30c ZBTB44 20.47 Zinc finger and BTB domain containing 41 Txn N
miR-30c CTGF/CCN2 ref. 67 Regulates chondrocyte and osteoblast differentiation and angiogenesis. TGF inducible. Dev EC
miR-30d GRP78/HSPA5 ref. ER stress response Chaperone ER
miR-30e BRWD1 20.9 WD repeat domain. bromo domain recognize acetylated lysine in histone Epige N
miR-30e PCGF5 20.51 polycomb group (PcG) ring fnger 5 Epige Chro
miR-30e HELZ 20.46 ZF RNA helicase RNA N
TargetScan was utilized for the prediction of targets and scoring. Listed factors are selected under score 20.4 and involved in development, RNA regulation, epigenetics
and transcription. Abbreviations: Phos Sig, phosphorylation signal; Dev, development; Txn, transcription; RNA, RNA regulation; Epige, epigenetics; Stem, stem cell
differentiation; C, cytoplasm; N, nucleoplasm; Chro, chromatin; EC, extracellular space; ER, endoplasmic reticulum.
doi:10.1371/journal.pone.0058796.t003
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level comparable to the initial level. Together with the data of
expression patterns in Fig 9 and Fig 2, miR-30 targets were
classified into several groups; immediate induction followed by
rapid attenuation group (ccn1/2/3, hnrnpa3 vC, eed, hspa5/grp78),
immediate reduction and rapid recovery group (runx2 and lifr), the
constant induction group (lin28a and opn/spp1) and the constant
reduction group (pcgf5 and hnrnpa3 vB).
Human miR-541 and miR-155 function and expression
pattern in hMSC/hMBSC osteoblastic differentiation
In order to investigate OstemiR expression in hMSC osteo-
blastic differentiation, qRT-PCR was carried out. miR-541 and
miR-155 were induced in 4 hours after the osteo-stimulation to
KUSA-A1, but not on the day 14 (Fig 3B, Fig 4). In addition, miR-
155 and miR-541 were gradually reduced during osteoblast
differentiation of hMSC (Fig 1H), while miR-541 level was higher
in osteo-induced cells on day 4 and day 14 compared with the
control (Fig 10A). In attempt to clarify a function of miR-541 and
miR-155 during osteogenesis of hMSC, we transiently transfected
these cells with antagonists/anti-miR targeting these two types of
miRNAs. The efficiency of anti-miR-155 or anti-miR-541
knockdown was of approximately 20–40% compared with the
control siRNA transfections (Fig 10B). Despite this apparently low
efficiency, a significant increase by 1.8-fold in the osteoblastic
marker OPN/SPP1 mRNA level was observed by miR-541 knock
down (Fig 10C). ALP mRNA level in anti-miR-541 transfectants
was higher than that in the control. In accordance, calcium
deposition on the anti-miR541-treated cells was more rich than
those of controls in a result of alizarin red S staining on day 7,
comparing center regions in each wells (Fig 10D). There were no
significant changes in ALP staining of upon miR-155 or miR-541
knock down. Taken together, these data indicate that miR-541 is a
negative regulator of osteoblast differentiation of hMSC.
Discussion
Tuning model of osteogenic factors by OstemiRs during
MSC osteogenesis
Together with these results and data interpretations, we propose
the tuning model of canonical and novel osteogenic factors by the
OstemiRs including miR-30 family and miR-541. In this model,
miR-30b/c represses hspa5, eed, ccn1/2/3, hnrnpa3 vC (Fig 11A),
opn/spp1, lin28a (Fig 11B), lifr and runx2 (Fig 11C) at the MSC
stage. This repression is released during osteogenesis upon
reduction of miR-30b/c, a change especially significantly in
increase in opn/spp1, lin28a (Fig 11B), lifr and runx2 (Fig 11C).
Osteo-inductive stimulation transiently induces hspa5, eed, ccn1/2/3
and hnrnpa3 vC, but thereafter those transcripts are attenuated by
miR-30b/c at the early stage and by miR-30a/d/e during the
osteocytic stage (Fig 11A). miR-30a/d/e targets pcgf5 and hnrnpa3
vB as well (Fig 11D). Human OPN/SPP1 in hBMSC/MSC is
attenuated by miR-541.
Figure 8. Analysis of miR-30 targeting. (A) Effects of miR-30d on mRNA levels in proliferating/sparse KUSA-A1 cells. Reduced and induced mRNA
was separately shown. vec, vector transfectant; 30d, miR-30d transfectant. (B) Effects of miR-30d on target mRNA levels in confluent KUSA-A1 cells.
*, P,0.05 (n=4). n.s., not significant.
doi:10.1371/journal.pone.0058796.g008
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The speed of mineralization was different among the cell types
tested: KUSA.hMSC.MC3T3 as shown in Fig 1. In addition,
Comparing expression patterns of opn/spp1 between KUSA and
hMSC/hBMSC, it was suggested that KUSA-A1 is most
committed to osteoblast lineage, or has a faster differentiation
process than hBMSC, which would contain more undifferentiated
cells and differentiation potential to other lineage. Thus, further
understanding and sorting MSC and BMSC are needed for
clinical application for bone regeneration, because those popula-
tions have potentials of aging/senescence, adipogenic and
chondrogenic differentiation as well.
The difference in speed or stage of differentiation may result in
difference in expression signature of miRNA, e.g., mouse miR-30d
was induced on 4 h or 14 days after the osteo-induction compared
with the control, while human miR-30d showed waving induction
and reduction during osteogenesis (Fig S2). Besides, mouse miR-
541 was strongly induced in 4 hours of initial induction, and then
reduced in the later stage (Fig 3B and Fig 4), while in hMSC, miR-
541 was gradually reduced in long culture, suggesting some role
for miR-541 in osteogenesis. In fact, knockdown of miR-541
upregulated OPN/SPP1 and mineralization. However, a direct
target site of miR-541 on OPN/SPP1 has not been identified yet,
indicating an unknown indirect mechanism.
Figure 9. mRNA expression patterns of miR-30 targets in mMSC line. (A) Relative expression levels of miR-30 target mRNA in proliferating/
sparse KUSA cells. Values were normalized to 18s rRNA levels. (B) Relative expression levels of miR-30 targets between proliferating and confluent
cells. *, P,0.05 (n=4). (C, D, E) Expression patterns of lin28a, pcgf5 (C), hnrnpa3 variant C, eed, hspa5/grp78 (D), runx2, lifr (E) and hnrnpa3 variant B (F)
during KUSA-A1 osteocytogenesis. *, P,0.05 (n=2). n.s., not significant.
doi:10.1371/journal.pone.0058796.g009
Figure 10. Expression and function of miR-541 and miR-155 during hBMSC/MSC osteogenesis. (A) Expression pattern of miR-541 and
miR-155 with (osteo) or w/o (control) osteo-induction. (B) Knock-down of miR-541 and miR-155. miRNA levels were normalized to Snord48 levels. (C)
Effect of anti-miR-541 or anti-miR-155 on OPN/SPP1 and ALP mRNA expression. Values were normalized to S29 mRNA levels. (D) Effect of anti-miR-541
and anti-miR155 on calcification (top row) and alkaline phosphatase production (ALP, bottom 2 rows). The thick stained part in the center by alizarin
red S was re-organized in the 2nd row.
doi:10.1371/journal.pone.0058796.g010
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Lin28A, hnRNPA3, Eed and Pcgf5
As targets of miR-30, we found novel key factors in osteogenesis
including Lin28, hnRNPA3, Eed, Pcgf5 and HspA5/Grp78. Here
we discuss about roles of these factors in bone formation as well as
canonical osteogenic factors including Runx2, LifR, Opn/Spp1
and the CCN family, which are the targets of miR-30d.
LIN28A is essential in induced pluripotent stem cells (iPSC) and
represses the let-7 tumor-suppressor miRNA family [40]. A recent
study proposed that Lin28 is essential in embryonic stem cells
(ESC), induced pluripotent stem cells (iPSC) and tumorigenesis
and that the expression of LIN28 is controled by let-7, miR-9,
miR-125 and miR-30 [41], indicating not only miR-30, but let-7,
miR-9 and miR-125 can control lin28a during osteogenesis.
Heterogeneous nuclear ribonucleoprotein (hnRNP) is another
crucial RNA regulator in RNA nuclear export and splicing.
hnRNPA1 directly associates with miR-18a stem-loop as well as
pri-miR-17/18a/19a, and then export pri-miR-17/18a/19a in the
exportin-independent manner [42]. Thereafter, hnRNPA1 pro-
motes cleavage of the miRNA by Drosha and Dicer. Furthermore,
hnRNPA1 inhibits processing of pri-let-7a by competing to KSRP,
which promote Drosha processing let-7a [43]. Nuclear export of
hnRNPA1 is promoted by phosphorylation in cells stressed by
osmic shock [44]. The role of hnRNPA3 is presumably similar to
that in hnRNPA1. In our study, only hnrnpa3 variant C was induced
upon osteo-induction, but not variant B, and context-dependent
effect of miR-30d on hnRNPA3 variants was suggested. Thus,
context- or osteoinduction-dependent hnRNP variants presumably
control mRNA splicing as well as the processing of miRNAs.
EED, named after embryonic ectoderm development, is
another novel target of miR-30. Eed is one of the main
components of polycomb repressive complex 2 (PRC2), which
induces histone H3K9 and K27 methylation leading to gene
repression. Recent studies revealed crucial roles of Eed in ESC
self-renewal through interaction with Stat3, Oct-3/4 and Sox2
[45,46]. Eed was also induced during osteo-induction in our study.
However, sox2, an ESC marker as well as an iPSC inducer, was
undetected in KUSA cells. Therefore, MSC was distinguished
from ESC or iPSC in this point, although our data suggested that
Eed-mediated silencing through histone methylation has still some
role in osteogenesis. PCGF5, a polycomb group ring finger protein
is involved in gene repression as well. This reduction of polycomb
factor PCGF5 during the osteogenesis may release expression of
osteocytogenic factors and miRNAs in an epigenetic manner.
miR-30 controls expression of LifR and Runx2, the known
regulators for osteoblasts
LIFR, the leukemia inhibitory factor receptor, is essential in
ESC self-renewal and in bone marrow stromal osteoblast
differentiation. Under physiological conditions, LIF is produced
from articular and growth plate cartilage, promoting proliferation
and differentiation of chondrocytes [47]. LIF from chondrocytes
influences vascularization during bone growth through promotion
of chondroclasts and osteoclasts. LIF produced in the marrow, and
by osteoblasts on the bone surface acts on stromal precursors to
inhibit adipogenesis, and stimulates osteoblasts on bone remodel-
ing surfaces. LIF also acts on osteocytes to inhibit production of
SOST/sclerostin. In pathology, LIF released by inflamed synovi-
um contributes to cartilage destruction by altering MMP
production, and is likely to induce osteoclastic bone erosions in
rheumatoid arthritis. As observed in Fig 11C, suppression of lifr
expression by miR-30 may control osteoblast and osteocyte
differentiation leading to attenuation of Lif/LifR/Jak-Stat signal.
Runt-related transcription factor 2 (Runx2) is a master
transcription factor for osteoblast/osteocyte differentiation and is
also known as core-binding factor subunit alpha-1 (CBFA1) and
Figure 11. Tuning model of canonical and novel osteogenic factors by miRNA-30 family and miR-541 during MSC osteogenesis.
miR-30b/c repress hspa5, eed, ccn1/2/3, hnrnpa3 vC (A), lin28a, opn/spp1 (B), lifr and runx2 (C) in MSC stage. This repression is released during
osteogenesis due to reduction of miR-30b/c, especially significantly in increase in opn/spp1, lin28a (B), lifr and runx2 (C). Osteo-induction transiently
induces hspa5, eed, ccn1/2/3 and hnrnpa3 vC, thereafter those transcripts are attenuated by miR-30b/c in early stage and by miR-30a/d/e in osteocytic
stage (A). miR-30a/d/e target hnrnpa3 vB and pcgf5 in osteoblastic and osteocytic stages (D). Human OPN/SPP1 in hBMSC/MSC is attenuated by miR-
541.
doi:10.1371/journal.pone.0058796.g011
microRNAs for MSC Osteogenic Differentiation
PLOS ONE | www.plosone.org 15 March 2013 | Volume 8 | Issue 3 | e58796acute myeloid leukemia 3 (AML3). Mutations in Runx2/Cbfa1
are associated with Cleidocranial dysplasia, which causes under-
development of bones and joints and multiple unerupted
supernumerary teeth. A previous study showed that runx2 is a
target of miR-30c, miR-135a, miR-204, miR-133a, miR-217,
miR-205, miR-34, miR-23a and miR-338 [34]. Our data also
indicate that miR-30b/c represses runx2 mRNA; however,
overexpression of miR-30d increased runx2 expression, through
unknown mechanisms. Runx2 and osterix are essential for osteo-
blastic differentiation. However, transcription factors that regulate
osteoblast maturation and/or osteocytic differentiation in late or
terminal differentiation stages have not yet been found. Thus, a
cohort of the OstemiR could be a crucial regulator of terminal
differentiation in the osteoblast lineage. Although runx2 is essential
for osteocytic differentiation, runx2 transgenic mice showed loss of
bone mass and osteocytes, suggesting that runx2 represses the late
stages of osteocytic differentiation [48]. By contrast, osterix/sp7 is
highly expressed in osteocytes, and conditional knockout of osterix
in mice resulted in a disorder of osteocytes and osterix target gene
expression [49]. It has been hypothesized that osteocytes have a
metabolostat role for homeostasis in bone [50]. Together with
these findings, not only vast expression of master transcription
factors but spacio-temporal diligent control by OstemiR would
contribute to development and homeostasis in bone. In order to
understand and control bone formation, other transcription factors
essential for osteoblast and osteocyte differentiation, e.g., Osterix/
Sp7 [51], Dlx3/Dlx5 [52,53] and Mef2c [31,54] as well as crucial
markers/factors for osteocytogenesis e.g. Sost/sclerostin, PTH1R,
FGF23, Phex, MEPE [55], Dmp and InsR/insulin signal [56].
Further investigation of OstemiR targeting on these osteogenic
factors is underway.
miR-30 controls CCN family gene expression during MSC
osteogenesis
Physiological production of CCN2/CTGF is more abundant
from chondrocytes in cartilage than those in other tissues, while
CCN1/2/3, the prototype members of CCN family, control both
chondrocytic and osteoblastic differentiation [57, 58). The
transient induction of ccn1/2/3 observed in this study could be
necessary and essential in initiation of MSC differentiation. A cis-
acting element of structure-anchored post-transcriptional repres-
sion (CAESAR) was identified in the 39-UTR of ccn2 in human
[59,60,61], then similar elements was found in mouse [60] and in
chicken [62,63]. In addition, miR-26ab/1297, miR-132/212,
miR-133, miR-18ab and miR-19, members of OstemiR, were
predicted to recognize the 39-UTR of ccn2/ctgf. Among this group,
miR-18 has been reported to control ctgf/ccn2 gene expression in
chondrocytic cells [64]. Dexamethasone has been shown to be a
strong inducer of ctgf/ccn2 [65,66]. In our study, ctgf/ccn2 was
immediately triggered after the osteo-induction treatment that
included dexamethasone, and then rapidly repressed in 2 days.
Therefore, immediate induction and subsequent rapid repression
of ctgf/ccn2 could be controlled by fluctuations in these miRNAs
including the miR-30 family. In myocardial cells CTGF/CCN2 is
regulated by miR-133 and miR-30c [67] and the 39-UTR of ctgf
and miR-30c are basepairing by 9 bases at 59 seed of miR-30c and
11 bases at 39 part including one of each GU non-Watson-Crick
base pairing (Fig 7A). In a result of direct analysis of ctgf/ccn2
mRNA, miR-30d reduced ctgf/ccn2 mRNA levels in confluent
KUSA-A1, while not in proliferating cells (Fig 8), indicating that
miR-30d attenuate basal ctgf/ccn2 level in idling MSCs.
Possible application of OstemiR for osteoporosis,
periodontitis and peri-implantitis
The OstemiR revealed in this study will be further clarified in
studies aimed at understanding and controlling distinct regulation
of MSC differentiation into not only osteocyte but also adipocytes,
chondrocytes, myoblasts and tendon/ligament cells. In fact, runx2
as well as sox9 a master transcription factor for chondrogenesis was
upregulated in mRNA level by miR-30d, indicating miR-30 could
direct differentiation of MSC. We focused on the miR-30 family
and miR-541 in this study, while still further analyzing roles of
OstemiR in MSC differentiation. Kawashima et al. analysed the
gene expression signature of KUSA-A1 cells using cDNA
microarray [33]. Comparing the protein coding gene and miRNA
expression signatures in future investigations could potentially
clarify target mRNAs of OstemiR. Combination of several
OstemiR or anti-OstemiR might regulate firmer cell differentia-
tion. miRNAs have the advantage of being smaller molecules than
proteins or antibodies and more easily synthesized or quantified
compared to the other molecules. Moreover, recent studies have
demonstrated that many miRNAs can be secreted [10]. Applica-
tion of OstemiRs could be useful for treatment of bone-related
diseases such as periodontitis, peri-implantitis and osteoporosis as
well as diagnosis.
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